Guidelines for management of atopic dermatitis

Hidehisa Saeki, Masutaka Furue, Fukumi Furukawa, Michihiro Hide, Mamitaro Ohtsuki, Ichiro Katayama, Rikako Sasaki, Hajime Suto, Kazuhiko Takehara

Research output: Contribution to journalReview article

178 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a chronic relapsing eczematous skin disease characterized by pruritus and inflammation and accompanied by cutaneous physiological dysfunction (dry and barrier-disrupted skin). Most of the patients have atopic diathesis. A standard guideline for the management (diagnosis, severity classification and therapy) of AD has been established. In our guideline, the necessity of dermatological training is emphasized in order to assure diagnostic skill and to enable evaluation of the severity of AD. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution; and (iii) chronic and chronically relapsing course. For the severity classification of AD, three elements of eruption (erythema/acute papules, exudation/crusts and chronic papules/nodules/lichenification) are evaluated in the most severely affected part of each of the five body regions (head/neck, anterior trunk, posterior trunk, upper limbs and lower limbs). The areas of eruption on the five body regions are also evaluated, and both scores are totaled (maximum 60 points). The present standard therapies for AD consist of the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation, topical application of emollients to treat the cutaneous physiological dysfunction, systemic antihistamines and anti-allergic drugs as adjunctive treatments for pruritus, avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. Tacrolimus ointment (0.1%) and its low-density ointment (0.03%) are available for adult patients and 2-15-year-old patients, respectively. The importance of the correct selection of topical corticosteroids according to the severity of the eruption is also emphasized. Furthermore, deliberate use of oral cyclosporine for severe recalcitrant adult AD is referred.

Original languageEnglish
Pages (from-to)563-577
Number of pages15
JournalJournal of Dermatology
Volume36
Issue number10
DOIs
Publication statusPublished - Oct 1 2009

Fingerprint

Atopic Dermatitis
Guidelines
Pruritus
Ointments
Body Regions
Tacrolimus
Skin
Eczematous Skin Diseases
Adrenal Cortex Hormones
Emollients
Inflammation
Anti-Allergic Agents
Histamine Antagonists
Disease Susceptibility
Therapeutics
Erythema
Upper Extremity
Cyclosporine
Counseling
Lower Extremity

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Saeki, H., Furue, M., Furukawa, F., Hide, M., Ohtsuki, M., Katayama, I., ... Takehara, K. (2009). Guidelines for management of atopic dermatitis. Journal of Dermatology, 36(10), 563-577. https://doi.org/10.1111/j.1346-8138.2009.00706.x

Guidelines for management of atopic dermatitis. / Saeki, Hidehisa; Furue, Masutaka; Furukawa, Fukumi; Hide, Michihiro; Ohtsuki, Mamitaro; Katayama, Ichiro; Sasaki, Rikako; Suto, Hajime; Takehara, Kazuhiko.

In: Journal of Dermatology, Vol. 36, No. 10, 01.10.2009, p. 563-577.

Research output: Contribution to journalReview article

Saeki, H, Furue, M, Furukawa, F, Hide, M, Ohtsuki, M, Katayama, I, Sasaki, R, Suto, H & Takehara, K 2009, 'Guidelines for management of atopic dermatitis', Journal of Dermatology, vol. 36, no. 10, pp. 563-577. https://doi.org/10.1111/j.1346-8138.2009.00706.x
Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I et al. Guidelines for management of atopic dermatitis. Journal of Dermatology. 2009 Oct 1;36(10):563-577. https://doi.org/10.1111/j.1346-8138.2009.00706.x
Saeki, Hidehisa ; Furue, Masutaka ; Furukawa, Fukumi ; Hide, Michihiro ; Ohtsuki, Mamitaro ; Katayama, Ichiro ; Sasaki, Rikako ; Suto, Hajime ; Takehara, Kazuhiko. / Guidelines for management of atopic dermatitis. In: Journal of Dermatology. 2009 ; Vol. 36, No. 10. pp. 563-577.
@article{e6ff886129644cc090c56e5e05a5f02f,
title = "Guidelines for management of atopic dermatitis",
abstract = "Atopic dermatitis (AD) is a chronic relapsing eczematous skin disease characterized by pruritus and inflammation and accompanied by cutaneous physiological dysfunction (dry and barrier-disrupted skin). Most of the patients have atopic diathesis. A standard guideline for the management (diagnosis, severity classification and therapy) of AD has been established. In our guideline, the necessity of dermatological training is emphasized in order to assure diagnostic skill and to enable evaluation of the severity of AD. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution; and (iii) chronic and chronically relapsing course. For the severity classification of AD, three elements of eruption (erythema/acute papules, exudation/crusts and chronic papules/nodules/lichenification) are evaluated in the most severely affected part of each of the five body regions (head/neck, anterior trunk, posterior trunk, upper limbs and lower limbs). The areas of eruption on the five body regions are also evaluated, and both scores are totaled (maximum 60 points). The present standard therapies for AD consist of the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation, topical application of emollients to treat the cutaneous physiological dysfunction, systemic antihistamines and anti-allergic drugs as adjunctive treatments for pruritus, avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. Tacrolimus ointment (0.1{\%}) and its low-density ointment (0.03{\%}) are available for adult patients and 2-15-year-old patients, respectively. The importance of the correct selection of topical corticosteroids according to the severity of the eruption is also emphasized. Furthermore, deliberate use of oral cyclosporine for severe recalcitrant adult AD is referred.",
author = "Hidehisa Saeki and Masutaka Furue and Fukumi Furukawa and Michihiro Hide and Mamitaro Ohtsuki and Ichiro Katayama and Rikako Sasaki and Hajime Suto and Kazuhiko Takehara",
year = "2009",
month = "10",
day = "1",
doi = "10.1111/j.1346-8138.2009.00706.x",
language = "English",
volume = "36",
pages = "563--577",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Guidelines for management of atopic dermatitis

AU - Saeki, Hidehisa

AU - Furue, Masutaka

AU - Furukawa, Fukumi

AU - Hide, Michihiro

AU - Ohtsuki, Mamitaro

AU - Katayama, Ichiro

AU - Sasaki, Rikako

AU - Suto, Hajime

AU - Takehara, Kazuhiko

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Atopic dermatitis (AD) is a chronic relapsing eczematous skin disease characterized by pruritus and inflammation and accompanied by cutaneous physiological dysfunction (dry and barrier-disrupted skin). Most of the patients have atopic diathesis. A standard guideline for the management (diagnosis, severity classification and therapy) of AD has been established. In our guideline, the necessity of dermatological training is emphasized in order to assure diagnostic skill and to enable evaluation of the severity of AD. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution; and (iii) chronic and chronically relapsing course. For the severity classification of AD, three elements of eruption (erythema/acute papules, exudation/crusts and chronic papules/nodules/lichenification) are evaluated in the most severely affected part of each of the five body regions (head/neck, anterior trunk, posterior trunk, upper limbs and lower limbs). The areas of eruption on the five body regions are also evaluated, and both scores are totaled (maximum 60 points). The present standard therapies for AD consist of the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation, topical application of emollients to treat the cutaneous physiological dysfunction, systemic antihistamines and anti-allergic drugs as adjunctive treatments for pruritus, avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. Tacrolimus ointment (0.1%) and its low-density ointment (0.03%) are available for adult patients and 2-15-year-old patients, respectively. The importance of the correct selection of topical corticosteroids according to the severity of the eruption is also emphasized. Furthermore, deliberate use of oral cyclosporine for severe recalcitrant adult AD is referred.

AB - Atopic dermatitis (AD) is a chronic relapsing eczematous skin disease characterized by pruritus and inflammation and accompanied by cutaneous physiological dysfunction (dry and barrier-disrupted skin). Most of the patients have atopic diathesis. A standard guideline for the management (diagnosis, severity classification and therapy) of AD has been established. In our guideline, the necessity of dermatological training is emphasized in order to assure diagnostic skill and to enable evaluation of the severity of AD. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution; and (iii) chronic and chronically relapsing course. For the severity classification of AD, three elements of eruption (erythema/acute papules, exudation/crusts and chronic papules/nodules/lichenification) are evaluated in the most severely affected part of each of the five body regions (head/neck, anterior trunk, posterior trunk, upper limbs and lower limbs). The areas of eruption on the five body regions are also evaluated, and both scores are totaled (maximum 60 points). The present standard therapies for AD consist of the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation, topical application of emollients to treat the cutaneous physiological dysfunction, systemic antihistamines and anti-allergic drugs as adjunctive treatments for pruritus, avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. Tacrolimus ointment (0.1%) and its low-density ointment (0.03%) are available for adult patients and 2-15-year-old patients, respectively. The importance of the correct selection of topical corticosteroids according to the severity of the eruption is also emphasized. Furthermore, deliberate use of oral cyclosporine for severe recalcitrant adult AD is referred.

UR - http://www.scopus.com/inward/record.url?scp=70349617974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349617974&partnerID=8YFLogxK

U2 - 10.1111/j.1346-8138.2009.00706.x

DO - 10.1111/j.1346-8138.2009.00706.x

M3 - Review article

C2 - 19785716

AN - SCOPUS:70349617974

VL - 36

SP - 563

EP - 577

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 10

ER -